uploads/2018/02/Chart-006-5-1.jpg

Sanofi’s Diabetes and Cardiovascular Products in 4Q17

By

Updated

Diabetes and cardiovascular products

Sanofi’s (SNY) diabetes and cardiovascular products include Lantus, Toujeo, Multaq, Praluent, and other drugs. These drugs reported revenues of ~1.3 billion euros in 4Q17, a 19.1% decline in operating revenues compared to 4Q16, excluding the revenues from emerging markets. 

The chart below compares the company’s Lantus sales and total revenues for Sanofi’s diabetes and cardiovascular franchise since 1Q16.

Article continues below advertisement

Diabetes products

Sanofi’s (SNY) diabetes products include Lantus and Toujeo. Diabetes products reported revenues of ~1.5 billion euros in 4Q17, a 15.6% decrease in operating revenues compared to 4Q16, including the revenues from emerging markets. 

Excluding the emerging markets sales, Sanofi’s diabetes products reported revenues of ~1.2 billion euros in 4Q17, a 21.1% decrease in operating revenues compared to 4Q16.

Lantus, an insulin glargine injection, reported revenues of 842.0 million euros in 4Q17. This trend is a 26.1% decline in operating revenues compared to 4Q16, excluding its emerging market sales. The decline was driven by lower sales from the US, Europe, and the rest of the world markets.

Toujeo reported revenues of 191.0 million euros in 4Q17, a 9.4% decline in operating revenues compared to 4Q16, excluding the emerging market sales. The decline was driven by lower sales in the US markets and substantially offset by strong sales from outside the US markets.

Other diabetes products in the market include Eli Lilly & Co.’s (LLY) Humulin injection, Novo Nordisk’s (NVO) NovoLog injection, Levemir injection, and Tresiba injection, and AstraZeneca’s (AZN) SymlinPen.

Cardiovascular products

Sanofi’s (SNY) cardiovascular products comprise two drugs: Multaq and Praluent. The combined revenues for these drugs totaled 130.0 million euros in 4Q17. This represents 6.9% growth in operating revenues compared to 4Q16, including the revenues from emerging markets. 

When excluding revenues from emerging markets, Sanofi’s cardiovascular products reported revenues of 127.0 million euros in 4Q17. The revenues for Multaq fell 12.9% to 75.0 million euros in 4Q17. Its Praluent sales rose 51.4% to 52.0 million euros in 4Q17.

Advertisement

More From Market Realist